CAIM
AMLX icon

Catherine Avery Investment Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Catherine Avery Investment Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56K Buy
+87
New +$1.34K ﹤0.01% 152
2026
Q1 		– Sell
-87
Closed -$1.05K – 112
2025
Q4 		$1.05K Hold
87
– – ﹤0.01% 142
2025
Q3 		$1.18K Hold
87
– – ﹤0.01% 144
2025
Q2 		$558 Hold
87
– – ﹤0.01% 158
2025
Q1 		$308 Hold
87
– – ﹤0.01% 156
2024
Q4 		$329 Buy
+87
New +$409 ﹤0.01% 167

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Catherine Avery Investment Management's AMLX Position: Q2 2026 in Review

Catherine Avery Investment Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 87 shares worth $1.56K. The stake represents ﹤0.01% of the portfolio and ranks #152 among its holdings. This is a return to the name: Catherine Avery Investment Management previously reported a position in AMLX as recently as Q4 2025.

Catherine Avery Investment Management first reported a position in AMLX in Q4 2024 and has held it in 6 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Catherine Avery Investment Management held 87 shares of Amylyx Pharmaceuticals worth $1.56K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Catherine Avery Investment Management position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Catherine Avery Investment Management's portfolio in Q2 2026, its #152 holding.
  • Catherine Avery Investment Management first reported a position in Amylyx Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Catherine Avery Investment Management's 13F filing for Q2 2026, filed 27 Jul 2026.